MYOV - Myovant slumps 20% on disappointing relugolix data in prostate cancer

Myovant Sciences (MYOV) drops 20% premarket on robust volume in reaction to outcome of an additional secondary endpoint in the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer.Relugolix failed to demonstrate superiority compared to leuprolide acetate as measured by the rate of castration resistance-free survival through week 48 (74% vs. 75%; p=0.84) in a subgroup of patients with metastatic disease.Nevertheless, the company remains optimistic for an FDA nod. Its marketing application is currently under review with an action date of December 20.

For further details see:

Myovant slumps 20% on disappointing relugolix data in prostate cancer